Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHIJIOKE NZE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1700315280
CMS profile
3222751
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$117.60

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $117.60 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Rigel Pharmaceuticals, Inc. $61.06 1
Janssen Research & Development, LLC $56.54 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHIJIOKE NZE

NPI 1700315280 · CMS profile ID 3222751

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700315280?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHIJIOKE NZE, NPI 1700315280, CMS profile ID 3222751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700315280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHIJIOKE NZE, NPI 1700315280, CMS profile ID 3222751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700315280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHIJIOKE NZE, NPI 1700315280, CMS profile ID 3222751, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700315280?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $117.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Rigel Pharmaceuticals, Inc. $61.0607/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962282351 CMS
Janssen Research & Development, LLC $56.5406/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887129707 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $117.60 2
PY2023 $105.39 1
PY2024 $391.42 6
PY2025 $301.11 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,345.47 2
PY2025 Principal investigator $1,218,012.54 51
PY2024 Principal investigator $609,810.03 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient F. Hoffmann-La Roche AG $914.44 12/12/2025 Covered Recipient Physician Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211535122
Recipient F. Hoffmann-La Roche AG $431.03 12/10/2025 Covered Recipient Physician Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211535126
Principal investigator 1 BeOne Medicines USA, Inc. $5,965.00 12/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327463
Principal investigator 1 Genentech, Inc. $37,873.00 11/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563438
Principal investigator 1 Genentech, Inc. $11,463.00 11/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563441
Principal investigator 1 BeOne Medicines USA, Inc. $1,981.00 11/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327465
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 11/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330171
Principal investigator 1 Genentech, Inc. $50,701.00 10/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563433
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 10/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336856
Principal investigator 1 BeOne Medicines USA, Inc. $8,058.00 09/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327457
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 09/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336895
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 09/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336900
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 08/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342199
Principal investigator 1 BeOne Medicines USA, Inc. $5,441.00 08/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327459
Principal investigator 1 BeOne Medicines USA, Inc. $19,979.00 07/22/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190327461
Principal investigator 1 Genentech, Inc. $36,758.00 07/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563427
Principal investigator 1 Genentech, Inc. $37,950.84 06/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563394
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 06/19/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342294
Principal investigator 1 BeOne Medicines Ltd. $1,439.81 06/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337026
Principal investigator 1 BeOne Medicines Ltd. $719.91 06/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337062
Principal investigator 1 BeOne Medicines USA, Inc. $27,939.52 06/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190339069
Principal investigator 1 BeOne Medicines USA, Inc. $4,253.00 05/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330987
Principal investigator 1 BeiGene, Ltd. $31,440.00 05/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323550
Principal investigator 1 BeiGene, Ltd. $1,439.81 05/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323552
Principal investigator 1 BeiGene, Ltd. $2,879.62 05/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323554
Principal investigator 1 Genentech, Inc. $1,458.68 05/02/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563423
Principal investigator 1 Genentech, Inc. $31,021.90 04/18/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563411
Principal investigator 1 BeiGene, Ltd. $2,879.62 04/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321948
Principal investigator 1 BeOne Medicines USA, Inc. $21,277.00 04/08/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330985
Principal investigator 1 BeiGene, Ltd. $78,600.00 04/07/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321878
Principal investigator 1 Genentech, Inc. $3,546.00 04/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563406
Principal investigator 1 Genentech, Inc. $47,827.00 04/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563415
Principal investigator 1 Genentech, Inc. $22,926.00 04/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563419
Principal investigator 1 BeOne Medicines USA, Inc. $42,161.00 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330983
Principal investigator 1 BeiGene, Ltd. $2,879.62 03/17/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321916
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321998
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325246
Principal investigator 1 BeiGene, Ltd. $6,479.15 03/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325248
Principal investigator 1 BeiGene, Ltd. $9,395.20 03/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325250
Principal investigator 1 BeiGene USA, Inc. $16,454.00 02/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190324568
Principal investigator 1 Genentech, Inc. $208,532.00 02/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563402
Principal investigator 1 BeiGene, Ltd. $34,450.88 02/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322030
Principal investigator 1 Genentech, Inc. $72,105.00 02/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211563398
Principal investigator 1 BeiGene, Ltd. $17,225.44 02/05/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322034
Principal investigator 1 BeiGene, Ltd. $15,720.00 02/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325312
Principal investigator 1 BeiGene, Ltd. $4,319.43 01/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323610
Principal investigator 1 BeiGene, Ltd. $4,319.43 01/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323648
Principal investigator 1 BeiGene, Ltd. $9,395.20 01/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323510
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323522
Principal investigator 1 BeiGene, Ltd. $4,319.43 01/15/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323526
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/15/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323528
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325322
Principal investigator 1 BeiGene, Ltd. $4,319.43 01/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325324